Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GRETEL TRULLENQUE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1720076144
CMS profile
32746
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$259.48

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.48 14

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GRETEL TRULLENQUE

NPI 1720076144 · CMS profile ID 32746

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GRETEL TRULLENQUE, NPI 1720076144, CMS profile ID 32746, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1720076144?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $259.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $22.2705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606133 CMS
AbbVie Inc. $16.1004/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796174807 CMS
Janssen Pharmaceuticals, Inc $19.9803/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606137 CMS
Janssen Pharmaceuticals, Inc $17.8502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788606135 CMS
PFIZER INC. $17.1402/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833592377 CMS
Novo Nordisk Inc $24.1702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810930157 CMS
GlaxoSmithKline, LLC. $20.3602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803009219 CMS
Merck Sharp & Dohme Corporation $16.6902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848464081 CMS
AbbVie Inc. $14.3301/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796174805 CMS
Lilly USA, LLC $20.0801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819179339 CMS
Lilly USA, LLC $16.2601/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818560599 CMS
Kowa Pharmaceuticals America, Inc. $17.7001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805594203 CMS
Amneal Pharmaceuticals LLC $16.4901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829682879 CMS
Novo Nordisk Inc $20.0601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811126305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.49 69
PY2020 $1,355.75 79
PY2021 $259.48 14
PY2022 $192.27 9
PY2023 $2,004.82 9
PY2024 $1,983.09 17
PY2025 $1,220.64 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,629,687.56 10
PY2024 Principal investigator $1,001,480.43 22
PY2023 Principal investigator $393,727.30 31
PY2022 Principal investigator $743,619.78 33
PY2021 Principal investigator $102,847.74 117
PY2020 Principal investigator $1,098,095.92 216
PY2019 Principal investigator $335,867.48 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Acella Pharmaceuticals, LLC $2,112.00 11/20/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766866
Principal investigator 1 Acella Pharmaceuticals, LLC $2,750.00 11/20/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766911
Principal investigator 1 Novartis Pharmaceuticals Corporation $178,933.58 11/10/2025 Non-covered Recipient Entity
FLORIDIAN RESEARCH INSTITUTE, LLC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190311117
Principal investigator 1 Acella Pharmaceuticals, LLC $1,250.00 08/28/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766713
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $605.11 06/24/2025 Non-covered Recipient Entity
Floridian Research Institute, Llc
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235997299
Principal investigator 1 Acella Pharmaceuticals, LLC $2,100.00 05/09/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766392
Principal investigator 1 Acella Pharmaceuticals, LLC $27,703.92 04/07/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766466
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $157,886.49 03/14/2025 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235997533
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $454,554.93 01/29/2025 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997535
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $801,791.53 01/17/2025 Non-covered Recipient Entity
Elias Research Associates Llc
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997531